[{"address1": "7800 Susquehanna St.", "address2": "Suite 505", "city": "Pittsburgh", "state": "PA", "zip": "15208", "country": "United States", "phone": "412 894 1853", "website": "https://www.lipella.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). LP-50, an intravesical formulation for local, intravesical PD-1 inhibition, intended for the treatment of non muscle invasive bladder cancer (NMIBC) Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan  Kaufman M.B.A., Ph.D.", "age": 57, "title": "Co-Founder, Chairman, CEO, President, Secretary & Treasurer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 233300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael B. Chancellor M.D.", "age": 65, "title": "Co-Founder, Chief Medical Officer & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 225000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas  Johnston CPA", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1985, "fiscalYear": 2024, "totalPay": 165000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michele  Gruber", "title": "Director of Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Janet  Okonski", "title": "Director of Clinical Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Katie  Johnston", "title": "Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.58, "open": 2.54, "dayLow": 2.54, "dayHigh": 2.74, "regularMarketPreviousClose": 2.58, "regularMarketOpen": 2.54, "regularMarketDayLow": 2.54, "regularMarketDayHigh": 2.74, "payoutRatio": 0.0, "beta": 0.306, "forwardPE": -0.828125, "volume": 68587, "regularMarketVolume": 68587, "averageVolume": 2182269, "averageVolume10days": 303940, "averageDailyVolume10Day": 303940, "bid": 1.93, "ask": 3.3, "bidSize": 2, "askSize": 2, "marketCap": 6754346, "fiftyTwoWeekLow": 1.965, "fiftyTwoWeekHigh": 12.0, "priceToSalesTrailing12Months": 12.593004, "fiftyDayAverage": 2.63186, "twoHundredDayAverage": 3.18413, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4617124, "profitMargins": 0.0, "floatShares": 2326759, "sharesOutstanding": 2548810, "sharesShort": 20718, "sharesShortPriorMonth": 58196, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.0081, "heldPercentInsiders": 0.09053001, "heldPercentInstitutions": 0.02894, "shortRatio": 0.43, "shortPercentOfFloat": 0.0089, "impliedSharesOutstanding": 2548810, "bookValue": 1.588, "priceToBook": 1.6687658, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -5016264, "trailingEps": -4.79, "forwardEps": -3.2, "lastSplitFactor": "1:8", "lastSplitDate": 1731024000, "enterpriseToRevenue": 8.608, "enterpriseToEbitda": -0.909, "52WeekChange": -0.54310346, "SandP52WeekChange": 0.07995045, "quoteType": "EQUITY", "currentPrice": 2.65, "targetHighPrice": 10.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.0, "targetMedianPrice": 10.0, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 2184863, "totalCashPerShare": 0.857, "ebitda": -5077656, "totalDebt": 47605, "quickRatio": 3.008, "currentRatio": 3.469, "totalRevenue": 536357, "debtToEquity": 2.48, "revenuePerShare": 0.512, "returnOnAssets": -1.0159401, "returnOnEquity": -1.9811901, "grossProfits": -3076830, "freeCashflow": -2109224, "operatingCashflow": -3950747, "revenueGrowth": 0.437, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -8.3568, "financialCurrency": "USD", "symbol": "LIPO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "longName": "Lipella Pharmaceuticals Inc.", "postMarketTime": 1745625347, "regularMarketTime": 1745611202, "exchange": "NCM", "messageBoardId": "finmb_35907207", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.713185, "regularMarketPrice": 2.65, "shortName": "Lipella Pharmaceuticals Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1671460200000, "postMarketChangePercent": 1.13207, "postMarketPrice": 2.68, "postMarketChange": 0.03, "regularMarketChange": 0.07000017, "regularMarketDayRange": "2.54 - 2.74", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 2182269, "fiftyTwoWeekLowChange": 0.68500006, "fiftyTwoWeekLowChangePercent": 0.34860054, "fiftyTwoWeekRange": "1.965 - 12.0", "fiftyTwoWeekHighChange": -9.35, "fiftyTwoWeekHighChangePercent": -0.7791667, "fiftyTwoWeekChangePercent": -54.310345, "cryptoTradeable": false, "epsTrailingTwelveMonths": -4.79, "epsForward": -3.2, "fiftyDayAverageChange": 0.018140078, "fiftyDayAverageChangePercent": 0.0068924935, "twoHundredDayAverageChange": -0.53412986, "twoHundredDayAverageChangePercent": -0.16774751, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-12-20", "displayName": "Lipella Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-04-26"}]